Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Why treating a few tumors may not control cancer elsewhere
Review or Meta-AnalysisA 2021 review asks whether immunotherapy could help control cancer beyond the few tumors treated with focused radiation.
-
Evidence date ·Skin lesions were inflammation while a pelvic mass was cancer
Clinical TrialTracked over timeBiopsies found sarcoid-like inflammation in two skin bumps, while a pelvic mass was confirmed as cancer. Immune-cell mapping revealed shared patterns and clear differences.
-
Evidence date ·What 80 reported cases reveal about confusing inflammation with cancer progression
Review or Meta-AnalysisTracked over timeOf 80 reported cases, 52 did not need the steroid prednisolone, while immunotherapy stopped in 44. The overlap between these groups is unknown.
-
Evidence date ·What did a biopsy reveal about this patient’s skin changes?
Review or Meta-AnalysisTracked over timeA biopsy confirmed cutaneous sarcoidosis during pembrolizumab and chemotherapy. Skin changes resolved after steroids while pembrolizumab continued less often.
-
Evidence date ·One melanoma patient recovered from COVID-19, leaving an open treatment question
Review or Meta-AnalysisA patient with metastatic melanoma recovered from COVID-19 after responding to immunotherapy. A review raises the possibility of continuing it when cancer is controlled.
-
Evidence date ·Why the medicine matters when watching for side effects in children with cancer
Review or Meta-AnalysisA review found pain and fever often reported with dinutuximab, while chemotherapy combinations and uneven toxicity reporting make drug comparisons uncertain.
-
Evidence date ·What did early COVID-19 studies find about cancer treatments and death?
Review or Meta-AnalysisA review of 16 studies linked active chemotherapy to higher odds of death in cancer patients with COVID-19; no clear link emerged for four other treatment categories.
-
Evidence date ·Why might a tiny drug carrier matter in cervical cancer care?
Review or Meta-AnalysisA 2021 review considers nanocellulose as a carrier for different cancer drugs and asks whether delivery design could make cervical cancer treatment gentler.
-
Evidence date ·What else matters when a nanoparticle reaches a tumour?
Review or Meta-AnalysisA 2021 review explains how tumour genetics, gut microbes, sex and age shape the immune setting in which nanoparticle cancer treatments are tested.
-
Evidence date ·Why pair immune checkpoint drugs with nanoparticles?
Review or Meta-AnalysisImmune checkpoint drugs help immune cells attack cancer but can cause serious adverse events. A 2021 review asks whether nanoparticles could carry them toward tumors.